Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation
about
sameAs
A randomised controlled trial of triple antiplatelet therapy (aspirin, clopidogrel and dipyridamole) in the secondary prevention of stroke: safety, tolerability and feasibilityESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - SummaryReappraisal of thienopyridine pretreatment in patients with non-ST elevation acute coronary syndrome: a systematic review and meta-analysisManagement of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology:Comparison of central adjudication of outcomes and onsite outcome assessment on treatment effect estimatesThe effect of preoperative treatment of P2Y12 receptor antagonists on perioperative bleeding and mortality in patients treated with coronary artery bypass grafting (CABG)Heparin versus placebo for non-ST elevation acute coronary syndromesAntiplatelet agents for chronic kidney diseaseThe effect of preoperative treatment of P2Y12 receptor antagonists on perioperative bleeding and mortality in patients treated with coronary artery bypass grafting (CABG)Antiplatelet agents for chronic kidney diseasePlatelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromesPlatelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromesAdenosine-diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes mellitusClopidogrel plus aspirin versus aspirin alone for preventing cardiovascular diseasePlatelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromesEarly invasive versus conservative strategies for unstable angina and non-ST elevation myocardial infarction in the stent eraClopidogrel plus aspirin versus aspirin alone for preventing cardiovascular diseaseCollaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patientsImpact of proton pump inhibitors on efficacy of clopidogrel: Review of evidenceAspirin and extended-release dipyridamole versus clopidogrel for recurrent strokeThe drug-drug interaction between proton pump inhibitors and clopidogrelEpidemiology, classification, and modifiable risk factors of peripheral arterial diseaseDebate: PCI or CABG for multivessel disease? Viewpoint: No clear winner in an unfair fightIncreased blood product use among coronary artery bypass patients prescribed preoperative aspirin and clopidogrelResistance to aspirin is increased by ST-elevation myocardial infarction and correlates with adenosine diphosphate levelsThe clopidogrel after surgery for coronary artery disease (CASCADE) randomized controlled trial: clopidogrel and aspirin versus aspirin alone after coronary bypass surgery [NCT00228423].Routine invasive strategies versus selective invasive strategies for unstable angina and non-ST elevation myocardial infarction in the stent eraDual antiplatelet therapy: optimal timing, management, and durationP2Y12-ADP receptor antagonists: Days of future and pastImpact of selective platelet inhibition in reducing cardiovascular risk - role of vorapaxarCurrent status of high on-treatment platelet reactivity in patients with coronary or peripheral arterial disease: Mechanisms, evaluation and clinical implicationsType 2 Diabetes and ADP Receptor Blocker TherapyShould dual antiplatelet therapy be used in patients following coronary artery bypass surgery? A meta-analysis of randomized controlled trialsAcute management of unstable angina and non-ST segment elevation myocardial infarctionComing safely to a stop: a review of platelet activity after cessation of antiplatelet drugsTIA Management: Should TIA Patients be Admitted? Should TIA Patients Get Combination Antiplatelet Therapy?Blood cells: an historical account of the roles of purinergic signallingAnticoagulants for secondary prevention after acute myocardial infarction: lessons from the past decadeRivaroxaban in patients with a recent acute coronary syndrome event: integration of trial findings into clinical practiceClopidogrel and proton pump inhibitors--where do we stand in 2012?
P2860
Q21144269-F6DFCF68-E8CC-4DC7-AB36-A6AC2DBCDAE0Q22241786-F9FCE61F-4CE0-4782-9279-FDE1A518B1C1Q22242057-076EAD46-5504-4233-97FA-1678AA68E3EAQ22242896-9AE57E68-B7AE-4B9A-9AFA-7F15FB583D6EQ24186056-365D1959-F211-4494-B277-937594A69546Q24187718-4A8FFB43-6083-4842-8EA2-40371B150D54Q24193744-F0C1BB90-305F-49CD-AC38-86210CD00299Q24197614-05C54B5F-8636-4DB3-9E7A-F9C49A08C6ADQ24197708-ECB55A85-248F-44BC-BC82-031EF39722EFQ24200752-E30123DF-1646-4D6D-A433-5651D57054FEQ24202522-0F98271E-BA9E-4AB2-9D15-62F77C5DBA6EQ24202999-41C91F9E-4065-4B77-BAF2-F03EC05D4733Q24203035-659EC586-B17F-4F85-A8CC-92AFD8C5C24EQ24234632-E90ABFC5-E6AA-41E3-A6CD-E67544DF04B5Q24235385-27519B7A-D1C9-4805-BD7C-25B8D54CD41DQ24236794-34E95115-1A6C-4AAD-A433-B75AAFDE95DEQ24243939-D99E1870-E102-448D-89C2-D9B629E0254EQ24555072-515458E8-44DD-4278-87C2-B568F2130961Q24608981-3B75F130-6723-4D95-B324-AD82FFE7CCFEQ24646522-2DB60648-68E7-4E3A-9A1A-48929600B92EQ24653812-D425B1E3-39FB-4012-B5E0-B6A64281EEB4Q24681271-8C655AC0-904B-47E9-B4A3-5EBADFDBDD92Q24799198-C16A0C82-AD27-48BB-B56E-B159BDEAA568Q24803138-BEFD0C09-0030-4D02-9282-43B072739B66Q24816368-052287AD-B346-444E-8ECC-D51A4004EDD1Q24816629-7DCEBD45-58F0-4243-886E-633543E40D9FQ26471900-B28C4BA1-11D8-43B7-B06C-8352DC13F2FAQ26741055-998AE6AE-D7FE-4652-9150-224C4FBA4FCCQ26745619-307271A3-F50D-4AC9-85E6-F4B5277CC323Q26745754-3D642423-3D58-4E1D-B33F-9406D6775A7FQ26771106-C08ADA86-7B94-4447-A830-63EB5113D2C5Q26772996-87653457-BCF3-410A-A3C1-0DA2D6D69D9CQ26782970-2A125E8E-D56C-45DF-AA01-6F1C6596D442Q26783157-60196122-9FDE-4488-8AF9-E3979F179ECCQ26795403-E5996540-1BE0-43F2-A87C-9A0EE77AE62CQ26796466-D803A60C-D511-4309-93C1-1E2BC8FA3951Q26799623-1D5000D7-80E0-4D8B-B495-8E18B88ABFCCQ26824864-9F98EA93-39F3-4B98-A2CE-3DA9366B60BDQ26825230-0C3B542F-25CD-4229-AA12-6D2A50E92CF8Q26825728-36217D88-AF72-483D-8D33-31167EE9946D
P2860
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation
description
2001 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2001
@ast
im August 2001 veröffentlichter wissenschaftlicher Artikel
@de
scientific article (publication date: 16 August 2001)
@en
vedecký článok (publikovaný 2001/08/16)
@sk
vědecký článek publikovaný v roce 2001
@cs
wetenschappelijk artikel (gepubliceerd op 2001/08/16)
@nl
наукова стаття, опублікована в серпні 2001
@uk
مقالة علمية (نشرت في 16-8-2001)
@ar
name
Effects of clopidogrel in addi ...... s without ST-segment elevation
@ast
Effects of clopidogrel in addi ...... s without ST-segment elevation
@en
Effects of clopidogrel in addi ...... s without ST-segment elevation
@nl
type
label
Effects of clopidogrel in addi ...... s without ST-segment elevation
@ast
Effects of clopidogrel in addi ...... s without ST-segment elevation
@en
Effects of clopidogrel in addi ...... s without ST-segment elevation
@nl
prefLabel
Effects of clopidogrel in addi ...... s without ST-segment elevation
@ast
Effects of clopidogrel in addi ...... s without ST-segment elevation
@en
Effects of clopidogrel in addi ...... s without ST-segment elevation
@nl
P2093
P921
P3181
P356
P1476
Effects of clopidogrel in addi ...... s without ST-segment elevation
@en
P2093
P304
P3181
P356
10.1056/NEJMOA010746
P407
P577
2001-08-16T00:00:00Z